Ibex Biosciences welcomes you to our Accredited Investor Regulation D Offering.
Ibex is pioneering breakthrough therapies for chemo-resistant colorectal cancer and malaria.
Watch the videos below, then enter the portal to learn more — and join us on this mission to transform global health!

Malaria | Pre-Clinical Result | Single Shot Cure

Current Market Size: $1.4B

Colon Cancer | Pre-Clinical Result | 98-99% Cancer Cell Inhibition

Current Market Size: $12.4B

Summary of the Offering

  • Minimum investment of $5,000
  • Half of the investment is in Ibex common stock, priced at a $37.5M pre-money valuation
  • Half of the investment is in an Ibex convertible note, paying 12% interest with a 20% equity conversion discount
  • Stock Certificate and Convertible Note are registered with CARTA
  • Open to accredited investors only
REGISTER NOW FOR MORE INFORMATION